Crescent Biopharma, Inc. Net Asset Quality Index
Crescent Biopharma, Inc. net asset quality index. Crescent Biopharma, Inc. (CBIO) has a Net Asset Quality Index of 89.3% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $182.76 Million minus total liabilities of $19.50 Million yields net assets of $163.25 Million. A higher index indicates a stronger, lower-leverage balance sheet. See Crescent Biopharma, Inc. book value and equity for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Crescent Biopharma, Inc. (2011–2025)
Net asset quality index of Crescent Biopharma, Inc. from 2011 to 2025. This chart shows how Crescent Biopharma, Inc.'s Net Asset Quality Index has evolved across 15 annual periods from 2011 to 2025. As of June 2026, the index stands at 89.3%, representing net assets of $163.25 Million against total assets of $182.76 Million USD. Check Crescent Biopharma, Inc. tangible equity quality to evaluate the tangible quality of the company's equity base.
Crescent Biopharma, Inc. Net Asset Quality Index by Year (2011–2025)
Crescent Biopharma, Inc. net asset quality index by year from 2011 to 2025. The table below presents the year-by-year Net Asset Quality Index for Crescent Biopharma, Inc. from 2011 to 2025, covering 15 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see how much is Crescent Biopharma, Inc. worth.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 84.5% | $203.01 Million | $240.29 Million | $37.28 Million | ▲ +127.9 pp |
| 2024 | -43.5% | $-15.48 Million | $35.62 Million | $51.10 Million | ▼ -128.2 pp |
| 2023 | 84.8% | $38.41 Million | $45.32 Million | $6.90 Million | ▲ +1.9 pp |
| 2022 | 82.9% | $42.93 Million | $51.81 Million | $8.88 Million | ▼ -3.6 pp |
| 2021 | 86.5% | $81.60 Million | $94.35 Million | $12.74 Million | ▼ -3.3 pp |
| 2020 | 89.8% | $128.22 Million | $142.83 Million | $14.61 Million | ▼ -2.0 pp |
| 2019 | 91.8% | $154.20 Million | $167.97 Million | $13.77 Million | ▼ -3.8 pp |
| 2018 | 95.6% | $205.46 Million | $214.84 Million | $9.38 Million | ▲ +2.5 pp |
| 2017 | 93.1% | $119.70 Million | $128.58 Million | $8.88 Million | ▲ +9.8 pp |
| 2016 | 83.3% | $35.30 Million | $42.39 Million | $7.09 Million | ▼ -0.2 pp |
| 2015 | 83.5% | $40.47 Million | $48.46 Million | $7.99 Million | ▼ -5.2 pp |
| 2014 | 88.7% | $50.80 Million | $57.26 Million | $6.46 Million | ▲ +33.7 pp |
| 2013 | 55.0% | $2.91 Million | $5.28 Million | $2.38 Million | ▼ -13.0 pp |
| 2012 | 68.0% | $12.53 Million | $18.42 Million | $5.89 Million | ▲ +38.8 pp |
| 2011 | 29.3% | $8.46 Million | $28.91 Million | $20.45 Million | — |